Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatsuro Suzuki has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Akio Niimi

    Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    3 shared publications
  • Hirotsugu Ohkubo

    Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    3 shared publications
  • Keima Ito

    Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    3 shared publications
  • Kensuke Fukumitsu

    Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    3 shared publications
  • Takehiro Uemura

    Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    3 shared publications
  • Tetsuya Oguri

    Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan

    3 shared publications

Latest Publications

  • Open Access

    Clinical Remission and Its Predictors After 12 Months of Biologic Therapy in Severe Asthma

    by Tatsuro Suzuki, Tomoko Tajiri, Yoshiyuki Ozawa, Yuki Amakusa, Keima Ito, Yuta Mori, Kensuke Fukumitsu, Satoshi Fukuda, Yoshihiro Kanemitsu, Takehiro Uemura, et al.

    Background/Objectives: The rates and predictors of clinical remission, a novel and practical therapeutic goal in severe asthma, have been inconsistently reported across studies. Data on clinical remission in Japanese patients remain limited. The aim of this study was to assess the rate of four-component clinical remission and its predictors in Japanese adult patients with severe asthma. Methods: This retrospective study enrolled adult patients with severe asthma who had initiated biologic therapy at least 12 months prior to inclusion at Nagoya City University Hospital. The primary endpoint was the achievement rate of four-component clinical remission, defined as (1) no maintenance oral corticosteroids (OCS); (2) no exacerbations for 12 months; (3) Asthma Control Test (ACT) score ≥ 20; and (4) forced expiratory volume in one second (FEV1) ≥ 80% of predicted. The secondary endpoint was to identify factors, including airway structural indices measured using chest computed tomography (CT), associated with clinical remission at 12 months. Results: Among 87 patients with severe asthma, 26 (30%) achieved four-component clinical remission after 12 months of biologic therapy. In univariate analysis, clinical remission was more frequently achieved in patients with chronic rhinosinusitis, higher FEV1 (% predicted), higher blood eosinophil counts, higher ACT scores, fewer exacerbations in the previous year, higher Lund–Mackay scores, and smaller airway wall thickness and luminal areas on CT (all p < 0.05). Multivariate analysis revealed that higher blood eosinophil counts and fewer exacerbations in the previous year were independently associated with clinical remission (both p < 0.05). Conclusions: After 12 months of biologic therapy, 30% of patients with severe asthma achieved four-component clinical remission. Higher blood eosinophil counts and fewer prior exacerbations were associated with higher remission rates.


  • Open Access

    Risk Factors for COVID-19 mRNA Vaccine-Associated Exacerbations in Patients With Obstructive Airway Diseases: REsearch for Asthma and COPD ExacerbaTION Caused by COVID-19 mRNA Vaccination (REACTION Study)

    by Tatsuro Suzuki, Yoshihiro Kanemitsu, Naoya Sugimoto, Katsunori Masaki, Taisuke Akamatsu, Hiroaki Tsurumaki, Suguru Majima, Keima Ito, Toshiyuki Iwata, Hideyasu Shimizu, et al.

    Suzuki T, et al. Allergy Asthma Immunol Res. 2026 May;18(3):362-378. https://doi.org/10.4168/aair.2026.18.3.362


  • Open Access

    COVID‐19 Vaccine‐Induced Severe Pneumonitis

    by Tatsuro Suzuki, Hiromi Furuta, Misa Naganawa, Keiko Hayashi, Hiroko Kiyotoshi, Chiharu Ohta, Shigemitsu Ninomiya

    Coronavirus disease 2019 (COVID‐19) has resulted in global morbidity, mortality, and societal disruption. COVID‐19 mRNA vaccination was mandatory in many countries for a period; however, severe adverse events have been observed in some individuals who received the vaccine. We report a case of COVID‐19 mRNA vaccine‐induced pneumonitis in a male patient whose cytokine levels were analysed prior to admission. His serum IgE level was high (347 U/mL), and several cytokines were elevated: TNFα was 1.2 pg/mL, IL‐6 was 156 pg/mL, and IL‐8 was 75.0 pg/mL. The patient developed severe respiratory failure requiring ventilatory support but recovered after steroid pulse therapy.


  • Open Access

    Dupilumab-Induced Remission in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: A 24-Month Study

    by Tomoko Tajiri, Motohiko Suzuki, Hirono Nishiyama, Yoshiyuki Ozawa, Yuki Amakusa, Tatsuro Suzuki, Keima Ito, Yuta Mori, Kensuke Fukumitsu, Satoshi Fukuda, et al.

    Background: When considering the effects of dupilumab on severe chronic rhinosinusitis with nasal polyps (CRSwNPs), dupilumab is expected to achieve CRSwNPs remission. The aim of this study was to assess the rate of remission of CRSwNPs with comorbid asthma and its predictors on a 24-month course of dupilumab. Methods: Adult patients with severe CRSwNPs and comorbid asthma who had completed a 24-month course of dupilumab were included in this post hoc analysis. The primary outcome was the rate of CRSwNPs remission at 12 and 24 months of dupilumab. The secondary outcome was to identify factors associated with CRSwNPs remission at 12 and 24 months. Based on the European criteria and a previous definition, remission was defined as the absence of symptoms, improved quality of life, no need for surgery, no exacerbations, recovery of olfactory function, and inactive disease by nasal endoscopy for ≥12 months. A rigorous six-component remission, including olfactory testing, was initially used. Results: Of 16 patients, 4 (25%) and 5 (31%) achieved six-component remission of CRSwNPs at 12 and 24 months, respectively. Patients with shorter disease duration and better olfactory function at baseline achieved six-component remission of CRSwNPs more frequently than those without at 24 months (both p < 0.05). Conclusions: Remission of severe CRSwNPs with comorbid asthma is attainable with a 24-month course of dupilumab.